No Detail Found!

Survival and Prognostic Factors in Limited-stage Small-cell Lung Cancer

Author(s)
Muhammed Mustafa Atci Department of Medical Oncology, University of Health Sciences, Professor Doctor Cemil Tascioglu Istanbul City Hospital,,Turkey
Abdullah Sakin Department of Medical Oncology, University of Health Sciences, Professor Doctor Cemil Tascioglu Istanbul City Hospital,,Turkey
Emre Uysal Department of Radiation Oncology, University of Health Sciences, Professor Doctor Cemil Tascioglu Istanbul City Hospital,,Turkey
Ferdi Aksaray Department of Radiation Oncology, University of Health Sciences, Professor Doctor Cemil Tascioglu Istanbul City Hospital,,Turkey
Oguzhan Selvi Department of Medical Oncology, University of Health Sciences, Professor Doctor Cemil Tascioglu Istanbul City Hospital,,Turkey
Orcun Can Department of Medical Oncology, University of Health Sciences, Professor Doctor Cemil Tascioglu Istanbul City Hospital,,Turkey
Abstract
Objective: To evaluate the factors a ecting overall survival (OS) and progression-free survival (PFS) in patients with limited stage-small cell lung cancer (LS-SCLC). Study Design: Descriptive study. Place and Duration of Study: Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey from January 2002 to October 2019. Methodology: Data of 89 patients was analysed, who were treated with chemoradiotherapy (CRT) for LS-SCLC,of whom some had also received prophylactic cranial irradiation (PCI). The clinical course and survival rates of LS-SCLS patients treated with di erent treatment modalities, were evaluated and the prognostic factors were analysed by Cox-regression analysis. Results: The median age of the patients was 59.6 (39 83) years-old; 82% were men. The median follow-up duration was 20 (1 189) months. The median PFS and OS were 16 (95% CI, 13-18) months and 33 (95% CI, 25-41) months. Patients, who underwent PCI had better OS compared to patients who did not [54 (95% CI, 27-87) monthsvs. 19 (95% Cl,, 13-25) months, log-rank, p = 0.004]. Grade 3-4 hematologic toxicities were observed in 12 (13.5%) patients and grade 3-4 esophagitis was observed in 25 (28.1%) patients. Younger age, ECOG 0-1, stage I-II disease, complete response to CRT were good prognostic factors on OS and PFS. A complete response to CRT was also a good independent factor in terms of PFS and OS. Conclusion: In this study, younger age, better ECOG status, stage I-II disease, and complete response to CRT had a favourable impact on OS and PFS in LS-SCLC. In addition, PCI has been shown to increase survival in these patients.
Publication Details
Page(s) 1433-1437
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 31, Issue: 12, Year: 2021

Request the full text from PASTIC

Keywords
Chemoradiotherapy, Thoracic radiotherapy, Small-cell lung cancer, Limited-stage
0

Citations

0

Downloads

75

Views